The effect of catecholamine depletion by alpha-methyl-para-tyrosine on measures of cognitive performance and sleep in abstinent MDMA users

Neuropsychopharmacology

Volumn 32, Issue 8, 2007, Pages 1695-1706

  McCann, Una D ^a   Peterson, Stephen C ^a   Ricaurte, George A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cognitive function; Dopamine; MDMA; Serotonin; Sleep

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CATECHOLAMINE; METIROSINE; SEROTONIN;

ACCURACY; ADULT; ARTICLE; CATECHOLAMINE BRAIN LEVEL; CATECHOLAMINE DEPLETION; CATECHOLAMINE NERVE CELL; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DEPTH PERCEPTION; FEMALE; HUMAN; IMPULSIVENESS; MALE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; SEROTONIN BRAIN LEVEL; SEROTONINERGIC NERVE CELL; SLEEP; TASK PERFORMANCE; VERBAL BEHAVIOR; WORKING MEMORY;

ADULT; ALPHA-METHYLTYROSINE; ANALYSIS OF VARIANCE; COGNITION; COMPUTER-ASSISTED INSTRUCTION; ELECTROENCEPHALOGRAPHY; ENZYME INHIBITORS; FEMALE; HALLUCINOGENS; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; PROLACTIN; RADIOIMMUNOASSAY; REACTION TIME; SLEEP; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 34447530500     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301302     Document Type: Article

References (73)

1. Allen RP, McCann UD, Ricaurte GA (1993). Persistent effects of (+/-)3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on human sleep. Sleep 16: 560-564.
2. Berg EA (1948). A simple objective technique for measuring flexibility in thinking. J Gen Psychol 39: 15-22.
3. Biello SM, Dafters RI (2001). MDMA and fenfluramine alter the response of the circadian clock to a serotonin agonist in vitro. Brain Res 920: 202-209.
4. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL (2002). Dose-related neurocognitive effects of marijuana use. Neurology 59: 1337-1343.
5. Bolla KI, Eldreth DA, Matochik JA, Cadet JL (2005). Neural substrates of faulty decision-making in abstinent marijuana users. Neuroimage 26: 480-492.
6. Bolla KI, McCann UD, Ricaurte GA (1998). Impaired memory function in abstinent MDMA ('Ecstasy') users. Neurology 51: 1532-1537.
7. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L et al (2003). Long-term effects of 'ecstasy' use on serotonin transporters of the brain investigated by PET. J Nucl Med 44: 375-384.
8. Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J et al (2004). A voxel-based PET investigation of the long-term effects of 'Ecstasy' consumption on brain serotonin transporters. Am J Psychiatry 161: 1181-1189.
9. Carskadon MA, Acebo C, Jenni OG (2004). Regulation of adolescent sleep: implications for behavior. Ann NY Acad Sci 1021: 276-291.
10. Casco C, Forcella M, Beretta G, Grieco A, Campana G (2005). Long-term effects of MDMA (Ecstasy) on the human central nervous system revealed by visual evoked potentials. Addict Biol 10: 187-195.
11. Chamberlain SR, Muller U, Blackwell AD, Clark L, Robbins TW, Sahakian BJ (2006). Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 311: 861-863.
12. Croft RJ, Mackay AJ, Mills AT, Gruzelier JG (2001). The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology 153: 373-379.
13. Dafters RI (2006). Chronic ecstasy (MDMA) use is associated with deficits in task-switching but not inhibition or memory updating executive functions. Drug Alcohol Depend 83: 181-184.
14. Esposito E (2006). Serotonin-dopamine interaction as a focus of novel antidepressant drugs. Curr Drug Targets 7: 177-185.
15. First MB, Spitzer RL, Gibbon M, Williams JB (1997). Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), Clinician Version. American Psychiatric Publishing, Inc.: Arlington, VA.
16. Gardani M, Blance RN, Biello SM (2005). MDMA alters the response of the mammalian circadian clock in hamsters: effects on re-entrainment and triazolam-induced phase shifts. Brain Res 1046: 105-115.
17. Gerra G, Bassignana S, Zaimovic A, Moi G, Bussandri M, Caccavari R et al (2003). Hypothalamic-pituitary-adrenal axis responses to stress in subjects with 3,4-methylenedioxy-methamphetamine ('ecstasy') use history: correlation with dopamine receptor sensitivity. Psychiatry Res 120: 115-124.
18. Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M, Neri E et al (2000). Long-lasting effects of (+/-)3,4 methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. Biol Psychiatry 47: 127-136.
19. Gerra G, Zaimovic A, Giucastro G, Maestri D, Monica C, Sartori R et al (1998). Serotonergic function after (+/-)3,4- methylenedioxymethamphetamine ('Ecstasy') in humans. Int Clin Psychopharmacol 13: 1-9.
20. Gottesman C (2004). Brain inhibitory mechanisms involved in basic and higher integrated sleep processes. Brain Res Brain Res Rev 45: 230-249.
21. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert HJ et al (2000). Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry 68: 719-725.
22. Gudelsky GA, Yamamoto BK (2003). Neuropharmacology and neurotoxicity of 3,4-methylenedioxymethamphetamine. Methods Mol Med 79: 55-73.
23. Harrison BJ, Olver JS, Norman TR, Burrows GD, Wesnes KA, Nathan PJ (2004). Selective effects of acute serotonin and catecholamine depletion on memory in healthy women. J Psychopharmacol 18: 32-40.
24. Hatzidimitriou G, McCann UD, Ricaurte GA (1999). Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 19: 5096-5107.
25. Heffernan TM, Jarvis H, Rodgers J, Scholey AB, Ling J (2001). Prospective memory, everyday cognitive failure and central executive function in recreational users of Ecstasy. Hum Psychopharmacol 16: 607-612.
26. Krystal JH, Price LH, Opsahl C, Ricaurte GA, Heninger GR (1992). Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? Am J Drug Alcohol Abuse 18: 331-341.
27. Matrenza C, Hughes JM, Kemp AH, Wesnes KA, Harrison BJ, Nathan PJ (2004). Simultaneous depletion of serotonin and catecholamines impairs sustained attention in healthy female subjects without affecting learning and memory. J Psychopharmacol 18: 21-31.
28. McCann UD, Eligulashvili V, Mertl M, Murphy DL, Ricaurte GA (1999). Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users. Psychopharmacology 47: 56-65.
29. McCann UD, Eligulashvili V, Ricaurte GA (2000). 3,4-Methylenedioxymeth- amphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 42: 11-16.
30. McCann UD, Penetar DM, Shaham Y, Thorne DR, Gillin JC, Sing HC et al (1992). Sleep deprivation and impaired cognition. Possible role of brain catecholamines. Biol Psychiatry 31: 1082-1097.
31. McCann UD, Ridenour A, Shaham Y, Ricaurte GA (1994). Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA 'Ecstasy'): a controlled study in humans. Neuropsychopharmacology 10: 129-138.
32. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA (1998). Positron emission tomographic evidence of toxic effect of MDMA ('Ecstasy') on brain serotonin neurons in human beings. Lancet 352: 1433-1437.
33. McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT et al (2005). Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology 30: 1741-1750.
34. Mejias S, Rossignol M, Debatisse D, Streel E, Servais L, Guerit JM et al (2005). Event-related potentials (ERPs) in ecstasy (MDMA) users during a visual oddball task. Biol Psychol 69: 333-352.
35. Millan MJ, Lejeune F, Gobert A (2000). Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J Psychopharmacol 14: 114-138.
36. Moeller FG, Barratt ES, Dougherty DM, Schmitz JM, Swann AC (2001). Psychiatric aspects of impulsivity. Am J Psychiatry 158: 1783-1793.
37. Morgan MJ (1998). Recreational use of 'ecstasy' (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 19: 252-264.
38. Morgan MJ (2000). Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berlin) 152: 230-248.
39. Morgan MJ, Impallomeni LC, Pirona A, Rogers RD (2006). Elevated impulsivity and impaired decision-making in abstinent Ecstasy (MDMA) users compared to polydrug and drug-naive controls. Neuropsychopharmacology 31: 1562-1573.
40. Newhouse PA, Belenky G, Thomas M, Thorne D, Sing HC, Fertig J (1989). The effects of d-amphetamine on arousal, cognition, and mood after prolonged total sleep deprivation. Neuropsychopharmacol 2: 153-164.
41. O'Brien EM, Mindell JA (2005). Sleep and risk-taking behavior in adolescents. Behav Sleep Med 3: 113-133.
42. O'Regan MC, Clow A (2004). Decreased pain tolerance and mood in recreational users of MDMA. Psychopharmacology 173: 446-451.
43. Parrott AC (2000). Human research on MDMA (3,4- methylenedioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change. Neuropsychobiology 42: 17-24.
44. Poland RE, Lutchmansingh P, McCracken JT, Zhao JP, Brammer GL, Grob CS et al (1997). Abnormal ACTH and prolactin responses to fenfluramine in rats exposed to single and multiple doses of MDMA. Psychopharmacol (Berlin) 131: 411-419.
45. Quednow BB, Kuhn KU, Hoppe C, Westheide J, Maier W, Daum I et al (2007). Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA ('Ecstasy'). Psychopharmacology (Berlin) 189: 517-530.
46. Rechstaffen A, Kales A (1968). A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. Government Printing Office: Washington, DC.
47. Reitan RM, Wolfson D (1993). The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Neuropsychology Press: Tucson, AZ.
48. Reneman L, Lavalaye J, Schmand B, de Wolff FA, van den Brink W, den Heeten GJ et al (2001). Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy'): preliminary findings. Arch Gen Psychiatry 58: 901-906.
49. Rey A (1964). L'examen Clinicque en Psychologie. Presses Universitaires de France; Paris.
50. Ricaurte GA, Delanney LE, Wiener SG, Irwin I, Langston JW (1988). 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of nonhuman primates. Brain Res 474: 359-363.
51. Ricaurte GA, McCann UD (2001). Experimental studies on 3,4 methylenedioxymethamphetamine (MDMA, 'ecstasy') and its potential to damage brain serotonin neurons. Neurotoxin Res 3: 85-99.
52. Robbins TW (2005). Chemistry of the mind: neurochemical modulation of prefrontal cortical function. J Comp Neurol 493: 140-146.
53. Rodgers J (2000). Cognitive performance amongst recreational users of 'ecstasy'. Psychopharmacology (Berlin) 151: 19-24.
54. Salkind NJ, Wright JC (1977). The development of reflection-impulsivity and cognitive efficiency: an integrated model. Hum Dev 20: 377-387.
55. Scheffel U, Szabo Z, Mathews WB, Finley PA, Dannals RF, Ravert HT et al (1998). In vivo detection of short- and long-term MDMA neurotoxicity - a positron emission tomography study in the living baboon brain. Synapse 29: 183-192.
56. Schmidt CJ, Wu L, Lovenberg W (1986). Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. Eur J Pharmacol 124: 175-178.
57. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC (1999). Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br J Psychiatry 175: 63-69.
58. Shankaran M, Gudelsky GA (1999). A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration. Psychopharmacol (Berlin) 147: 66-72.
59. Simon NG, Mattick RP (2002). The impact of regular ecstasy use on memory function. Addiction 97: 1523-1529.
60. Steele T, McCann U, Ricaurte GA (1994). 3,4-Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): pharmacology and toxicology in animals and humans. Br J Addict 89: 539-551.
61. Stone DM, Stahl DC, Hanson GR, Gibb JW (1986). The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 128: 41-48.
62. Stroop JR (1935). Studies of interference in serial verbal reactions. J Exp Psychol 18: 643-661.
63. Taylor EM (1959). Psychological Appraisal of Children with Cerebral Deficits. Harvard University Press: Cambridge, MA.
64. Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L et al (2003). Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology 167: 85-96.
65. Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L et al (2006). Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol 20: 211-225.
66. Thorne DR, Genser SG, Sing HC, Hegge FK (1985). The walter reed performance assessment battery. Neurobehav Toxicol Teratol 7: 415-418.
67. Verkes RJ, Gijsman HJ, Pieters MS, Schoemaker RC, de Visser S, Kuijpers M et al (2001). Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology 153: 196-202.
68. Virden TB, Baker LE (1999). Disruption of the discriminative stimulus effects of S(+)-methylenedioxymeth-amphetamine (MDMA by (+/-)-MDMA neurotoxicity: protection by fluoxetine. Behav Pharmacol 10: 195-204.
69. Volmm B, Richardson P, McKie S, Elliott R, Deakin JF, Anderson IM (2006). Serotonergic modulation of neuronal responses to behavioural inhibition and reinforcing stimuli: an fMRI study in healthy volunteers. Eur J Neurosci 23: 552-560.
70. von Geusau NA, Stalenhoef P, Huizinga M, Snel J, Ridderinkhof KR (2004). Impaired executive function in male MDMA ('ecstasy') users. Psychopharmacology 175: 331-341.
71. Wechsler D (1981). Wechsler Adult Intelligence Scale-Revised: Manual. Psychological Corp: New York, NY.
72. Wechsler D (1987). Wechsler Memory Scale-Revised: Manual. Psychological Corp: New York, NY.
73. Zakzanis KK, Young DA (2001). Memory impairment in abstinent MDMA ('Ecstasy') users: a longitudinal investigation. Neurology 56: 966-969.